COMMUNIQUÉS West-GlobeNewswire

Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial
13/11/2017
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq: LPTX ), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the third [...]
Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne
13/11/2017
NEW HAVEN, Conn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics , Inc. (NASDAQ: MLNT ) a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, [...]
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
13/11/2017
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969 ) in children and adults with Leber’s congenital amaurosis 10 (LCA 10). [...]
Spero Therapeutics Announces Underwriters’ Option Exercise
13/11/2017
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO ), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel [...]
Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union
13/11/2017
CARMIEL, Israel, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update
13/11/2017
Expansion of pipeline with two new antibodies against proteins alpha-synuclein and TDP-43 Recruitment of first cohort completed for anti-beta vaccine targeting Alzheimer's symptoms in adults with Down syndrome Strong [...]
Jounce Therapeutics Reports Third Quarter 2017 Financial Results
13/11/2017
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointments - - Update full year financial guidance - - Company to [...]
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017
13/11/2017
Total Revenues for Third Quarter were $22.9 million, an 18% Increase Total revenues for first 9 months of 2017 were $67.1 million, a 26% Increase On Track to Achieve $100 Million in Total Revenues in 2017 Guiding to $ [...]
Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs
13/11/2017
Higher Rates of Myocardial Infarction (Heart Attack) and Revascularization Procedures in Patients with High Triglycerides Were Drivers of the Composite Outcome MACE Rate 35% Higher in Patients Who, Despite Statin [...]
Fennec Provides Business Update And Reports Third Quarter 2017 Results
13/11/2017
During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study Study met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing loss without any [...]
Notice of Annual General Meeting
13/11/2017
Please see enclosed pdf.
Anthem Inc. Issues Positive Coverage Decision for Balloon Sinus Dilation
13/11/2017
PLYMOUTH, Minn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ: ENTL ), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that Anthem, Inc. now [...]
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs
13/11/2017
ZUG, Switzerland and CAMBRIDGE, Mass. and TÜBINGEN, Germany, and BOSTON, Nov. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a genome editing company focused on creating transformative gene-based [...]
Veritas and Cannevert Hires the Essèntium Group as Their Agent in Puerto Rico USA
13/11/2017
VANCOUVER, British Columbia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces that the Company through its research arm, Cannevert [...]
NANOBIOTIX présente de nouveaux résultats cliniques et précliniques confirmant le potentiel de NBTXR3 en Immuno-Oncologie, lors du congrès annuel du SITC
13/11/2017
Nanobiotix présente de nouveaux résultats cliniques et précliniques confirmant le potentiel de NBTXR3 en Immuno-Oncologie, lors du congrès annuel du SITC NBTXR3 activé par la radiothérapie induit une réponse [...]
NANOBIOTIX presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting
13/11/2017
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting NBTXR3 activated by radiotherapy induces a significant adaptive immune [...]
Xbrane Biopharma releases interim report for the period July to September 2017
13/11/2017
Press release 2017-11-13 Xbrane Biopharma ABs interim report for the period July - September 2017 is now available on the Company's website, www.xbrane.com . July to September Revenue SEK -47 thousand (-) EBITDA SEK -8, [...]
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13/11/2017
RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a robust data package, even in [...]
argenx to Present at Upcoming Investor Conferences
13/11/2017
November 13, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Pages